HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that in order to meet the needs of cancer patients in the United States, the Company has substantially increased its manufacturing capacity of FUSILEV®(levoleucovorin) for injection, since its approval for use in advanced metastatic colorectal cancer. Spectrum has qualified and maintains multiple third-party manufacturing facilities approved by the U.S. Food & Drug Administration (FDA) for the Company’s oncology drug, FUSILEV, which was approved in 2011 for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.
